Merck's Investigational Chronic Hepatitis C Combination Therapy...

Interim analysis of hard-to-cure1 patients administered MK-5172/MK-8742 with and without ribavirin for 12 or 18 weeks showed sustained viral response2 , 4 to 8 weeks after the completion of therapy : HCV GT1 infected, treatment-naive cirrhotic patients, MK-5172/MK-8742 treated - 97 percent for 12 and 18 weeks, and MK-5172/MK-8742 plus RBV - 90 ... (more)

http://ift.tt/R8iD51